Startups
CODA Biotherapeutics launched in South San Francisco with a $19 million Series A financing.
Once again, Amgen is accepting submissions for the 2018 Amgen-LabCentral Golden Ticket competition.
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.
Alcon, the Novartis eye care business, is leaving its longtime home of Texas for Switzerland. The company said it will move its corporate headquarters from Fort Worth to Geneva following the spinoff from Novartis.
It’s been a hot year for biotech initial public offerings (IPOs). Two recent announced offerings, Kodiak Sciences in Palo Alto and Guardant Health in Redwood City mark the fourteenth and fifteenth life sciences IPOs in the San Francisco Bay Area this year.
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
In January, it was announced that five healthcare systems were launching a not-for-profit generic drug company. That company now has a name, Civica Rx.
On August 29, Chicago-based Tempus, which focuses on data analytics for molecular and clinical data, announced it had raised $110 million in Series E financing. This brought total money raised so far to $320 million. This also gave the company a valuation of $2 billion.
RootPath, headquartered in Cambridge, Massachusetts, announced a $7 million seed funding round. The financing was led by Sequoia China. Volcanics Venture, BV (Baidu Ventures) and NestBio Ventures participated.
PRESS RELEASES